MET and cancer: Given the importance of juxtamembrane (JM) regions in controlling the active-state of many RTKs (Hubbard, 2004; Zhang et al., 2006; Jura et al., 2009; Cabail et al., 2015; Wybenga-Groot et al., 2001; Wiesner et al., 2006) and the prevalence of exon 14 skipping within the JM of MET in cancer (Lu et al., 2017), we were interested in how patterns of mutational sensitivity from the DMS could relate the JM to potential MET regulatory mechanisms.